Fenofibrate and Propranolol in Burn Patients

• Status: Terminated
• Trial end date: 2019-07-12
• Target enrollment: 0
• Participant gender: All

Summary

The proposed study will test the hypothesis that Propranolol, fenofibrate and fenofibrate plus propranolol have therapeutic, physiological, and metabolic effects that will improve clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Medical Branch, Galveston
• Collaborators: National Institute of General Medical Sciences (NIGMS); Shriners Hospitals for Children
• Treatments: Fenofibrate; Metoprolol; Propranolol

Criteria

Inclusion Criteria:

• 0 through 80 years

• ≥ 20% Total Body Surface Area Burn injury

Exclusion Criteria:

Pregnancy

History or existence of pre-burn injury conditions

• Allergies to propranolol or fenofibrate

• Asthma requiring treatment

• Congestive heart failure (measured ejection fraction < 20%)

• Renal or hepatic disease

• Medical condition requiring glucocorticoid treatment

• History of AIDS, Aids Related Complex or HIV

• History of Cancer within 5 years

Decision not to treat due to burn injury severity or futility as deemed by the clinical team